Gene therapy targets in heart failure: the path to translation

Heart failure (HF) is the common end point of cardiac diseases. Despite the optimization of therapeutic strategies and the consequent overall reduction in HF-related mortality, the key underlying intracellular signal transduction abnormalities have not been addressed directly. In this regard, the ga...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Raake, Philip (VerfasserIn) , Tscheschner, Henrike (VerfasserIn) , Reinkober, J. (VerfasserIn) , Ritterhoff, Julia (VerfasserIn) , Katus, Hugo (VerfasserIn) , Koch, W. J. (VerfasserIn) , Most, Patrick (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 24 August 2011
In: Clinical pharmacology & therapeutics
Year: 2011, Jahrgang: 90, Heft: 4, Pages: 542-553
ISSN:1532-6535
DOI:10.1038/clpt.2011.148
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/clpt.2011.148
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1038/clpt.2011.148
Volltext
Verfasserangaben:P.W.J. Raake, H. Tscheschner, J. Reinkober, J. Ritterhoff, H.A. Katus, W.J. Koch, P. Most
Beschreibung
Zusammenfassung:Heart failure (HF) is the common end point of cardiac diseases. Despite the optimization of therapeutic strategies and the consequent overall reduction in HF-related mortality, the key underlying intracellular signal transduction abnormalities have not been addressed directly. In this regard, the gaps in modern HF therapy include derangement of β-adrenergic receptor (β-AR) signaling, Ca2+ disbalances, cardiac myocyte death, diastolic dysfunction, and monogenetic cardiomyopathies. In this review we discuss the potential of gene therapy to fill these gaps and rectify abnormalities in intracellular signaling. We also examine current vector technology and currently available vector-delivery strategies, and we delineate promising gene therapy structures. Finally, we analyze potential limitations related to the transfer of successful preclinical gene therapy approaches to HF treatment in the clinic, as well as impending strategies aimed at overcoming these limitations. Clinical Pharmacology & Therapeutics (2011) 90 4, 542-553. doi:10.1038/clpt.2011.148
Beschreibung:Gesehen am 08.09.2022
Beschreibung:Online Resource
ISSN:1532-6535
DOI:10.1038/clpt.2011.148